China Reform Financials
| 000503 Stock | 13.01 0.24 1.88% |
China | Select Account or Indicator |
Understanding current and past China Reform Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of China Reform's financial statements are interrelated, with each one affecting the others. For example, an increase in China Reform's assets may result in an increase in income on the income statement.
Please note, the presentation of China Reform's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, China Reform's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of China Reform's management manipulating its earnings.
China Reform Stock Summary
China Reform competes with Ningbo Construction, Shannon Semiconductor, Giantec Semiconductor, Semiconductor Manufacturing, and Nexchip Semiconductor. China Reform is entity of China. It is traded as Stock on SHE exchange.Specialization | Health Care, Health Care Equipment & Services |
| Instrument | China Stock View All |
| Exchange | Shenzhen Stock Exchange |
| ISIN | CNE000000255 |
| Business Address | No 18 Xilijia, |
| Sector | Health Care Providers & Services |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.crhms.cn |
| Phone | 86 10 5782 5333 |
You should never invest in China Reform without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of China Stock, because this is throwing your money away. Analyzing the key information contained in China Reform's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
China Reform Key Financial Ratios
China Reform's financial ratios allow both analysts and investors to convert raw data from China Reform's financial statements into concise, actionable information that can be used to evaluate the performance of China Reform over time and compare it to other companies across industries.| Revenue | 330.13 M | ||||
| Gross Profit | 85.24 M | ||||
| EBITDA | (87.35 M) | ||||
| Net Income | (79.79 M) | ||||
| Total Asset | 1.95 B |
China Reform Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 1.3B | 1.2B | 1.1B | 2.0B | 2.2B | 1.4B | |
| Other Current Liab | 2.0K | 2.0K | 281.9M | 1.5K | 1.7K | 1.6K | |
| Net Debt | (446.6M) | (303.1M) | (114.3M) | (734.1M) | (660.7M) | (627.7M) | |
| Accounts Payable | 2.3M | 4.3M | 8.3M | 25.7M | 23.2M | 24.3M | |
| Cash | 496.7M | 352.9M | 169.5M | 928.1M | 1.1B | 1.1B | |
| Net Receivables | 76.4M | 111.1M | 183.5M | 206.6M | 237.6M | 397.0M | |
| Inventory | 10.5K | 5.1K | (419.9M) | 2.0M | 1.8M | 1.0M | |
| Other Current Assets | 15.2M | 9.5M | 3.8M | 2.4M | 2.2M | 2.3M | |
| Total Liab | 332.6M | 405.1M | 391.7M | 530.2M | 477.2M | 501.0M | |
| Total Current Assets | 1.0B | 877.2M | 776.3M | 1.6B | 1.8B | 1.9B | |
| Short Term Debt | 50.1M | 47.7M | 51.6M | 193.3M | 173.9M | 182.6M | |
| Intangible Assets | 147.2M | 144.1M | 152.7M | 175.1M | 201.3M | 152.4M | |
| Retained Earnings | 179.1M | 1.0M | (83.5M) | (163.0M) | (187.5M) | (178.1M) | |
| Net Tangible Assets | 1.4B | 823.8M | 657.7M | 591.0M | 531.9M | 822.8M | |
| Net Invested Capital | 1.0B | 820.6M | 756.4M | 1.6B | 1.4B | 918.9M | |
| Net Working Capital | 697.8M | 474.2M | 388.1M | 1.1B | 955.3M | 577.6M |
China Reform Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 507.9K | 2.5M | 2.0M | 5.1M | 5.9M | 6.2M | |
| Total Revenue | 207.4M | 252.5M | 311.1M | 330.1M | 297.1M | 199.0M | |
| Operating Income | (117.4M) | (132.7M) | (109.9M) | (106.6M) | (95.9M) | (91.1M) | |
| Cost Of Revenue | 176.9M | 218.7M | 246.6M | 248.1M | 285.4M | 299.6M | |
| Income Before Tax | (242.8M) | (176.9M) | (83.2M) | (78.4M) | (70.6M) | (67.0M) | |
| Net Income | (242.6M) | (175.8M) | (84.5M) | (79.8M) | (71.8M) | (68.2M) | |
| Income Tax Expense | 506.2K | 523.2K | 203.3K | 1.3M | 1.1M | 1.1M | |
| Minority Interest | 3.1M | 1.3M | (7.3K) | 527.5K | 474.7K | 451.0K | |
| Research Development | 16.4M | 16.3M | 9.6M | 967.9K | 871.2K | 827.6K | |
| Gross Profit | 30.5M | 33.8M | 64.5M | 82.0M | 94.3M | 99.0M | |
| Ebit | (173.1M) | (129.4M) | (132.7M) | (109.9M) | (98.9M) | (103.9M) | |
| Tax Provision | 523.2K | 203.3K | 1.3M | 1.9M | 1.7M | 1.6M | |
| Net Interest Income | 7.5M | 764.1K | (601.9K) | (4.7M) | (4.2M) | (4.0M) | |
| Interest Income | 8.2M | 4.3M | 1.6M | 628.2K | 565.4K | 537.1K | |
| Ebitda | 48.8M | (210.0M) | (138.1M) | (41.6M) | (37.4M) | (39.3M) |
China Reform Key Cash Accounts
Cash flow analysis captures how much money flows into and out of China Reform Health. It measures of how well China is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money China Reform brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money China had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what China Reform has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Capital Expenditures | 17.7M | 23.1M | 37.7M | 52.1M | 46.9M | 49.0M | |
| Net Income | (242.6M) | (175.8M) | (84.5M) | (79.8M) | (71.8M) | (68.2M) | |
| Change To Inventory | 27.5K | 5.4K | 5.1K | (2.0M) | (1.8M) | (1.7M) | |
| Investments | 51.4M | (29.2M) | 10.6M | (51.9M) | (46.8M) | (44.4M) | |
| Change In Cash | (219.0M) | (146.0M) | (185.6M) | 754.1M | 867.2M | 910.5M | |
| Depreciation | 32.3M | 36.3M | 39.6M | 33.8M | 38.8M | 24.0M | |
| Change To Netincome | (25.7M) | 131.6M | 47.0M | (24.0M) | (27.6M) | (28.9M) | |
| End Period Cash Flow | 493.0M | 347.0M | 161.4M | 915.4M | 823.9M | 485.3M | |
| Free Cash Flow | (110.7M) | (127.9M) | (197.9M) | (154.3M) | (177.4M) | (186.3M) | |
| Other Non Cash Items | 5.7M | 6.6M | 4.3M | 5.7M | 5.1M | 5.8M |
China Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining China Reform's current stock value. Our valuation model uses many indicators to compare China Reform value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across China Reform competition to find correlations between indicators driving China Reform's intrinsic value. More Info.China Reform Health is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value China Reform by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for China Reform's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.China Reform Health Systematic Risk
China Reform's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. China Reform volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on China Reform Health correlated with the market. If Beta is less than 0 China Reform generally moves in the opposite direction as compared to the market. If China Reform Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one China Reform Health is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of China Reform is generally in the same direction as the market. If Beta > 1 China Reform moves generally in the same direction as, but more than the movement of the benchmark.
China Reform Health Total Assets Over Time
China Reform Thematic Clasifications
China Reform Health is part of Health Management investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Healthcare providers, hospitals. Major hospitals and healthcare providers
This theme covers Healthcare providers, hospitals. Major hospitals and healthcare providers. Get More Thematic Ideas
| Health Management | View |
China Reform March 17, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of China Reform help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of China Reform Health. We use our internally-developed statistical techniques to arrive at the intrinsic value of China Reform Health based on widely used predictive technical indicators. In general, we focus on analyzing China Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build China Reform's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.03 | |||
| Information Ratio | 0.0337 | |||
| Maximum Drawdown | 17.38 | |||
| Value At Risk | (4.48) | |||
| Potential Upside | 6.19 |
Complementary Tools for China Stock analysis
When running China Reform's price analysis, check to measure China Reform's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China Reform is operating at the current time. Most of China Reform's value examination focuses on studying past and present price action to predict the probability of China Reform's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China Reform's price. Additionally, you may evaluate how the addition of China Reform to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |